Uncovering druggable hotspots on Pin1 via X-ray crystallographic fragment screening

Qingjie Xiao1, Jianchao Tang1, Huangliang Shu2

  • 1National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201210, People's Republic of China.

Insights

Fragment screening identified new ways to inhibit Pin1, a key protein in cancer. This research expands the potential for developing targeted anticancer drugs by revealing novel binding sites and fragment chemotypes.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Medicinal Chemistry

Background:

  • Pin1 is a crucial enzyme in cell cycle regulation and signal transduction, implicated in tumorigenesis.
  • Overexpression of Pin1 in various cancers makes it a promising therapeutic target.
  • The shallow binding surface of Pin1 poses challenges for traditional drug design.

Purpose of the Study:

  • To overcome design challenges by employing structure-based fragment screening.
  • To identify novel druggable binding pockets and fragment scaffolds for Pin1 inhibition.
  • To guide the development of selective and effective Pin1 inhibitors.

Main Methods:

  • X-ray crystallography-based fragment screening of a curated library.
  • Identification and analysis of approximately 50 Pin1-fragment complex structures.
  • Enzymatic inhibition assays and mass spectrometry for validation.

Main Results:

  • Discovery of druggable binding hotspots, including the catalytic center (Site 1) and a neighboring region (Site 2).
  • Identification of fragments exhibiting cooperative binding across multiple sites.
  • Confirmation of covalent binding modes for reactive fragments targeting Cys113.
  • Validation of fragment-based inhibition of Pin1 activity in solution.

Conclusions:

  • Systematic mapping of functional binding pockets expands the druggable landscape of Pin1.
  • Identified key structural features and fragment chemotypes for inhibitor design.
  • Provides a foundation for developing novel, selective, and multifunctional Pin1 inhibitors for cancer therapy.